Advertisement
Singapore markets close in 3 hours 20 minutes
  • Straits Times Index

    3,193.31
    +38.62 (+1.22%)
     
  • Nikkei

    38,036.14
    +74.34 (+0.20%)
     
  • Hang Seng

    16,398.80
    +146.96 (+0.90%)
     
  • FTSE 100

    7,847.99
    +27.63 (+0.35%)
     
  • Bitcoin USD

    61,468.94
    -2,783.47 (-4.33%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,022.21
    -29.20 (-0.58%)
     
  • Dow

    37,753.31
    -45.66 (-0.12%)
     
  • Nasdaq

    15,683.37
    -181.88 (-1.15%)
     
  • Gold

    2,390.90
    +2.50 (+0.10%)
     
  • Crude Oil

    82.87
    +0.18 (+0.22%)
     
  • 10-Yr Bond

    4.5850
    -0.0740 (-1.59%)
     
  • FTSE Bursa Malaysia

    1,544.32
    +3.90 (+0.25%)
     
  • Jakarta Composite Index

    7,149.97
    +19.13 (+0.27%)
     
  • PSE Index

    6,536.19
    +86.15 (+1.34%)
     

Pfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?

Pfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?

The company also continues to benefit from sales of blockbusters including blood thinner Eliquis and oncology drug Ibrance. In fact, Pfizer expects patent losses alone to lead to $17 billion in lost revenue from 2025 through 2030. In spite of these upcoming obstacles, is Pfizer still a buy?